glp-1 and substance use disorder medications get at the heart of addiction: study – WashU Medicine GLP-1s Reduced Risk of Developing
Description
Clinical efficacy data is therefore extrapolated from the brand evidence rather than directly demonstrated for the compounded version
[DOI] [PubMed] [Google Scholar] 288.Conceicao J., Dores J., Araujo F., Laires P.A., Carr R.D., Brodovicz K., Radican L., Nogueira A.M
[DOI] [PubMed] [Google Scholar] 65.Mei J., Sun J., Wu J., Zheng X
Am Heart J 2010
the escalation schedule and safety monitoring were integral to those results
Pharmacological Background Pharmacologic treatments have evolved from toxic early options like dinitrophenol and amphetamines to modern drugs including orlistat, naltrexone, bupropion, phentermine, topiramate, and GLP-1RAs [11]
